BOA (University of Milano-Bicocca) · 2022 · 25 citations · 28 references
Veterinary MedicineImmunologyInfectious DiseasesAntibody EngineeringImmunopharmacologyVirologyAntibody DiscoveryAntibody Specificity EngineeringViral InfectionsViral PathologyEarly Intervention RegimesFab Antibody FragmentsIntranasal AdministrationIntranasal ApproachSars-cov-2 InfectionSevere Acute Respiratory SyndromeSingle-chain Variable FragmentsTreatment Of Coronavirus Infections
As of December 2021, coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a global emergency, and novel therapeutics are urgently needed. Here we describe human single-chain variable fragment (scFv) antibodies (76clAbs) that block an epitope of the SARS-CoV-2 spike protein essential for ACE2-mediated entry into cells. 76clAbs neutralize the Delta variant and other variants being monitored (VBMs) and inhibit spike-mediated pulmonary cell-cell fusion, a critical feature of COVID-19 pathology. In two independent animal models, intranasal administration counteracted the infection. Because of their high efficiency, remarkable stability, resilience to nebulization, and low cost of production, 76clAbs may become a relevant tool for rapid, self-administrable early intervention in SARS-CoV-2-infected subjects independently of their immune status.
28
Molecular Cloning. A Laboratory Manual
EJ Wood · Biochemical Education · 1983 · 30.6K citations
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
Delphine Planas, David Veyer, Artem Baidaliuk et al. · Nature · 2021 · 2.2K citations · Full text